Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

Effect of MS treatment on cognitive dysfunction

November 15, 2018

…ression of cognitive impairment. Annual screening for depression is also recommended. The authors noted that few pivotal trials of disease-modifying therapies have included cognitive outcome measures; interpretation of these data is hampered by the short duration of the studies and methodological issues. The largest study on cognition and DMT use was COGIMUS, which reported that the proportion of patients with cognitive impairment remained stable…

Overview of long-term data in RRMS

November 7, 2018

…e received >2 additional courses. ARR at year 8 was 0.18; 85% were relapse-free and 64% were free from 6-month confirmed disability progression. The mean change in EDSS score from core study baseline to year 8 was 0.17; 70% had stable or improved (47%) EDSS scores. In year 8, 89% had no Gd+ lesions and 70% had no new/enlarging T2 lesions. The median cumulative brain volume loss from baseline was -1.06%; brain volume loss was -0.19%/year or less in…

Oral cladribine recommended for public reimbursement in Canada

November 6, 2018

…(4-5 days) per year for two years; the cumulative dose is 3.5 mg/kg. The recommendation for public reimbursement was based on CADTH’s Canadian Drug Expert Committee (CDEC) review of the phase III CLARITY trial (Giovannoni et al. N Engl J Med 2010;362:416-426). In that study, cladribine was superior to placebo in reducing the annualized relapse rate (57% reduction) and was associated with a decreased risk of three-month confirmed disease progressio…

ECTRIMS 2018 SLIDE DECK

October 25, 2018

…no permissions are required prior to use. As a courtesy, we would like to ask that you provide us with feedback after your presentation(s). This will help us to fine-tune free educational resources that NeuroSens develops in the future. Click here to complete the feedback questionnaire…

ECTRIMS 2018 DAILY REPORT – WEDNESDAY EDITION

October 10, 2018

…:1719-1731; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC5070917/pdf/nihms802765.pdf). Benefits have been maintained during the 48-month open-label extension (De Seze et al. ECTRIMS 2018; abstract P592). In the group receiving continuous biotin, the proportion with an improvement in disability was 13% at month 18, 8% at month 24, and 13% at months 36 and 42. For the group switched from placebo to biotin, the percentages were 7% at month…